- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
DiaMedica Therapeutics Inc (DMAC)
DiaMedica Therapeutics Inc stock price live, this page displays NASDAQ DMAC stock exchange data. View the DMAC premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the DiaMedica Therapeutics Inc real time stock price chart below.
What Is the DiaMedica Therapeutics Inc Stock Price Today?
The DiaMedica Therapeutics Inc stock price today is 6.950.
What Is the Stock Symbol for DiaMedica Therapeutics Inc?
The stock symbol for DiaMedica Therapeutics Inc is ""DMAC.""
What Stock Exchange Does DiaMedica Therapeutics Inc Trade On?
DiaMedica Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is DiaMedica Therapeutics Inc a Good Stock to Buy?
Determining whether DiaMedica Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DMAC quote. (ISIN: CA25253X2077)
What Is the DiaMedica Therapeutics Inc Stock Price Today?
The DiaMedica Therapeutics Inc stock price today is 6.950.
What Is the Stock Symbol for DiaMedica Therapeutics Inc?
The stock symbol for DiaMedica Therapeutics Inc is ""DMAC.""
What Stock Exchange Does DiaMedica Therapeutics Inc Trade On?
DiaMedica Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is DiaMedica Therapeutics Inc a Good Stock to Buy?
Determining whether DiaMedica Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DMAC quote. (ISIN: CA25253X2077)
NASDAQ
Currency in USD
6.950
-0.110(-1.56%)
Real-time Data·
Fair Value
An estimate of a DiaMedica Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.915
7.100
52 wk Range
3.190
7.490
DMAC Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
DMAC is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a DiaMedica Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.9157.100
52 wk Range
3.1907.490
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
DMAC Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a DiaMedica Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
12.333
Upside
+77.46%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings upwards for the upcoming period
- Form 8K DiaMedica Therapeutics Inc For: 12 August
- Investing.com
- Form 8K DiaMedica Therapeutics Inc For: 12 August
- Investing.com
- DiaMedica names Julie Krop as chief medical officer
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
DiaMedica Therapeutics Inc Company Profile
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company also develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
DiaMedica Therapeutics Inc Earnings Call Summary for Q2/2025
- Q2 EPS loss of $0.18, beating forecast of $0.19 loss; no revenue reported. Stock initially fell 3.83% but recovered to $5.22.
- $30M private placement bolsters cash position, extending runway to 2027. Strong liquidity with 7.55 current ratio despite ongoing losses.
- Positive interim results for DM199 in Phase 2 preeclampsia trial. FDA IND application for Phase 2B trial planned, with US start in 2026.
- REMEDY two stroke trial progressing; interim analysis of first 200 patients expected Q2 2026. Expansion to UK and Europe underway.
- New CMO Dr. Julie Krop highlights KLK1 protein's dual role. CEO expresses confidence in DM199 as potential first-in-class preeclampsia treatment.
Last Updated: 13/08/2025, 13:56
Read Full TranscriptCompare DMAC to Peers and Sector
Metrics to compare | DMAC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDMACPeersSector | |
|---|---|---|---|---|
P/E Ratio | −12.2x | −5.2x | −0.7x | |
PEG Ratio | 0.39 | −0.04 | 0.00 | |
Price/Book | 13.3x | 2.1x | 2.6x | |
Price / LTM Sales | - | 42.8x | 3.4x | |
Upside (Analyst Target) | 70.0% | 125.0% | 37.8% | |
Fair Value Upside | Unlock | −2.5% | 5.5% | Unlock |
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 12.333
(+77.46% Upside)
Earnings
Latest Release
Aug 12, 2025
EPS / Forecast
-0.18 / -0.19
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does DiaMedica Therapeutics Trade On?
DiaMedica Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for DiaMedica Therapeutics?
The stock symbol for DiaMedica Therapeutics is "DMAC."
What Is the DiaMedica Therapeutics Market Cap?
As of today, DiaMedica Therapeutics market cap is 359.24M.
What Is DiaMedica Therapeutics's Earnings Per Share (TTM)?
The DiaMedica Therapeutics EPS (TTM) is -0.69.
When Is the Next DiaMedica Therapeutics Earnings Date?
DiaMedica Therapeutics will release its next earnings report on 04 Nov 2025.
From a Technical Analysis Perspective, Is DMAC a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has DiaMedica Therapeutics Stock Split?
DiaMedica Therapeutics has split 1 times.
How Many Employees Does DiaMedica Therapeutics Have?
DiaMedica Therapeutics has 28 employees.
What is the current trading status of DiaMedica Therapeutics (DMAC)?
As of 14 Oct 2025, DiaMedica Therapeutics (DMAC) is trading at a price of 6.950, with a previous close of 7.06. The stock has fluctuated within a day range of 6.915 to 7.100, while its 52-week range spans from 3.190 to 7.490.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.